• POWERPOINT PRESENTATION
  Sustained antiretroviral efficacy of raltegravir as part of combination ART in treatment-naive HIV-1 infected patients:
  96-week data
  M Markowitz
  Poster Presentation
• POWERPOINT POSTER PRESENTATION
  Trends of integrase inhibitors drug resistance in treatment-naive patients with HIV-1 subtype C infection in Brazil
  C Passaes
  Poster Presentation
• failure to control viral replication in the brain
  D. Armstrong-James
  Abstract
• High rate of virologic success with raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients
  with multidrug-resistant virus: results of the ANRS 139 TRIO trial
  Y. Yazdanpanah, C. Fagard, D. Descamps, et al
  Abstract
• RAL-KAL: pharmacokinetics (PK) of coadministered raltegravir (RAL) and lopinavir-ritonavir...
  F. Rhame , M. Long , E. Acosta, et al
  Abstract
• Development of hepatic cytolysis after switching from enfuvirtide to raltegravir in virologically suppressed patients treated
  with tipranavir/ritonavir
  H. Khanlou, C. Allavena, E. Billaud, et al
  Abstract
• Clinical experience with raltegravir (MK-0518 or Isentress), with an optimised background regimen in highly
  treatment-experienced patients
  A. Teague, C. Scott, T. Youngstein, et al
  Abstract
• Pilot study of switching enfuvirtide to raltegravir in HIV-1 positive patients well controlled on an enfuvirtide based regimen
  W. Towner, D. Klein, S. Follansbee, et al

• POSTER
  48-Week Results from BENCHMRK-2, a Phase III Study of Raltegravir in Patients Failing ART
  with Triple-class Resistant HIV
  R Steigbigel, P Kumar, J Eron, et al
  PDF Poster      Abstract
• POSTER
  48-Week Results from BENCHMRK-1, a Phase III Study of Raltegravir in Patients Failing ART with
  Triple-class Resistant HIV-1
  D Cooper, J Gatell, J Rockstroh, , et al
  PDF Poster      Abstract
• POSTER
  Phenotypic Susceptibility in vitro to Raltegravir and Elvitegravir and Polymorphism of the Integrase
  Gene of HIV-2 Clinical Isolates
  B Roquebert, F Damond, G Collin, G Peytavin
  PDF Poster      Abstract
• More Pronounced Effect of Integrase Inhibitor Raltegravir on Proviral DNA Reduction that other
  Antiretroviral Drugs in Patients Achieving Undetectable Viremia
  S Arponen, J Benito, S Lozano, et al
  Abstract
• Outcomes of Patients Switched from Enfuvirtide to Raltegravir within a Virologically Suppressive Regimen
  M Harris, G Larsen, J Montaner
  Abstract
•  

• First report of raltegravir (RAL, MK-0518) use after virologic rebound on elvitegravir (EVT, GS 9137)
  DeJesus E, Cohen C, Elion R., et al
  Abstract
• Rapid onset and durable antiretroviral effect of raltegravir (MK-0518), a novel HIV-1 integrase
  inhibitor, as part of combination ART in treatment HIV-1 infected patients: 48-week data
  Markowitz M, Nguyen B-Y2, Gotuzzo E, et al
  Abstract
• The integrase inhibitor raltegravir alters viral decay kinetics of HIV, significantly reducing
  the second phase and challenging current hypotheses of viral replication
  Murray JM, Emery S, Kelleher A, et al
  Abstract

• Results of BENCHMRK-1, a Phase III Study Evaluating the Efficacy and Safety of MK-0518, a Novel
  HIV-1 Integrase Inhibitor, in Patients with Triple-class Resistant Virus
  D Cooper, J Gatell, J Rockstroh, et al
  Abstract
• Results of BENCHMRK-2, a Phase III Study Evaluating the Efficacy and Safety of MK-0518, a Novel
  HIV-1 Integrase Inhibitor, in Patients with Triple-class Resistant Virus
  R Steigbigel, P Kumar, J Eron, et al
  Abstract

• Prediction of human pharmacokinetics for a series of potent and selective HIV integrase inhibitors
  leading to development of MK-0518 for the treatment of AIDS
  Laufer R., Taliani M., Di Marco A., et al
  Abstract
• Discovery of MK-0518 a novel, potent and selective HIV integrase inhibitor in phase III clinical trials
  Summa V., Pace P., Petrocchi A., et al
  Abstract
• Biochemical and antiviral activity of MK-0518, a potent HIV integrase inhibitor
  Miller M., Witmer M., Stillmock K
  Abstract
• Preclinical pharmacokinetics and metabolism of MK-0518, a potent HIV Integrase inhibitor in phase
  III clinical trials
  Laufer R., Odalys Gonzalez-Paz, Marina Taliani, et al
  Abstract

Raltegravir Conference Citations